(Reuters) - Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it.
Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday.
17:59 How Sears CEO Lampert cashes in as stores cash out21
21:05 Houston home building rises while commercial projects fall in February20
19:53 Costco Wholesale expands test of home grocery delivery through new third-party service20
13:08 Tesla raises $1.2 billion, 20 percent more than planned20